242 related articles for article (PubMed ID: 11125280)
1. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
3. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
7. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
10. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
11. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
[TBL] [Abstract][Full Text] [Related]
13. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
14. nm23 expression in tissue sections and tumor effusion cells of ovarian neoplasms.
Harłozińska A; Bar JK; Gerber J
Int J Cancer; 1996 Oct; 69(5):415-9. PubMed ID: 8900377
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
[TBL] [Abstract][Full Text] [Related]
17. p21WAF1/CIP1 protein expression in primary ovarian cancer.
Ferrandina G; Stoler A; Fagotti A; Fanfani F; Sacco R; De Pasqua A; Mancuso S; Scambia G
Int J Oncol; 2000 Dec; 17(6):1231-5. PubMed ID: 11078810
[TBL] [Abstract][Full Text] [Related]
18. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Ueno Y; Enomoto T; Otsuki Y; Sugita N; Nakashima R; Yoshino K; Kuragaki C; Ueda Y; Aki T; Ikegami H; Yamazaki M; Ito K; Nagamatsu M; Nishizaki T; Asada M; Kameda T; Wakimoto A; Mizutani T; Yamada T; Murata Y
Cancer Lett; 2006 Sep; 241(2):289-300. PubMed ID: 16459017
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.
Nakayama K; Takebayashi Y; Nakayama S; Hata K; Fujiwaki R; Fukumoto M; Miyazaki K
Cancer Lett; 2003 Mar; 192(2):227-35. PubMed ID: 12668287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
